ZYVERSA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $55.87 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $55.87K, a 22.71% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $73.99K, a 53.95% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $59.20K, a 63.15% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $72.29K, a 67.67% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $222.83K, a 68.42% decline from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $705.57K, a 40.86% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.19M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 1 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $55.87K 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $222.83K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $73.99K 10-Q · filed 2025-11-19 | $133.19K derived: sum of 2 quarters · filed 2025-11-19 | $205.48K derived: sum of 3 quarters · filed 2026-05-13 | ||
| 2025-06-30 | $59.20K 10-Q · filed 2025-11-19 | $131.49K derived: sum of 2 quarters · filed 2026-05-13 | |||
| 2025-03-31 | $72.29K 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | $705.57K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $160.66K 10-Q · filed 2025-11-19 | $321.33K derived: sum of 2 quarters · filed 2025-11-19 | $544.90K derived: sum of 3 quarters · filed 2025-11-19 | ||
| 2024-06-30 | $160.66K 10-Q · filed 2025-11-19 | $384.24K derived: sum of 2 quarters · filed 2025-11-19 | |||
| 2024-03-31 | $223.57K 10-Q · filed 2025-11-19 | ||||
| 2023-12-31 | $1.19M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $243.04K 10-Q · filed 2024-11-14 | $608.79K derived: sum of 2 quarters · filed 2024-11-14 | $896.25K derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $365.74K 10-Q · filed 2024-11-14 | $653.20K derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $287.46K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $56.33K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |